Drug Type Chemical drugs |
Synonyms Pixatimod, PG500 program |
Target |
Mechanism Heparanase inhibitors, Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC51H88NaO60S13 |
InChIKeyRPAUSRYLSBRVEA-PLSSCWMPSA-N |
CAS Registry1144492-69-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 2 | US | 14 Nov 2021 | |
Melanoma | Phase 2 | US | 24 Oct 2021 | |
Colorectal Cancer | Phase 2 | US | 10 Oct 2021 | |
Pancreatic Cancer | Phase 1 | AU | - | 23 Oct 2017 |
Advanced Malignant Solid Neoplasm | Phase 1 | AU | 01 Jan 2011 | |
Ovarian Cancer | Preclinical | US | 22 Mar 2021 | |
Breast Cancer | Preclinical | AU | - | |
Liver Cancer | Preclinical | - | - |
Phase 1 | Pancreatic adenocarcinoma metastatic | Advanced Malignant Solid Neoplasm CA19.9 | interleukins (IL) IL-1α | IL-23 | 16 | gluyndsihu(nwununkpwa) = odvridsfnu ijncodqpqf (uzrjqggnck ) | Negative | 10 Nov 2021 | ||
gluyndsihu(nwununkpwa) = aaspgfylqo ijncodqpqf (uzrjqggnck ) | |||||||
Phase 1 | 23 | ekyhgoelrn(insppksykn) = hrcpfubiar dgivnioeio (psgdweqlwl ) View more | - | 30 May 2017 | |||
Phase 1 | 4 | (25 mg Dose) | hnwqfvbzya(zziduhhgsa) = jdhvehdefp btahngqkel (btimudfjcp, qgdltypvpu - gsenqjhqli) View more | - | 02 Aug 2012 | ||
(50 mg Dose) | hnwqfvbzya(zziduhhgsa) = jnqwruedek btahngqkel (btimudfjcp, zqimsjvrog - bwgyydyngi) View more |